

PORTFOLIO
NEWSLETTER

MAY
2021

NIHR University College London Hospital Clinical Research Facility Cancer Trials



INSIDE THIS ISSUE:

- COVID-19 1
- Referral Information 2
- Open Studies 3

COVID-19 and Early Phase Cancer Trials at UCLH

During this difficult time we are trying to keep the early phase cancer trials program open to enrolment. The CRF is a geographically distinct unit to the main hospital and patients are treated in individual rooms as much as possible to minimize infection risk.

We therefore continue to welcome referrals; however due to the pressures at the front line, we are running at limited capacity and may not be able to take your patient immediately. Please liaise with the PI of the study you are considering referring to.

This newsletter provides you with details of the current ongoing cancer trials.



*Dr. Rakesh Popat, Consultant Haematologist
Cancer Lead NIHR UCLH Clinical Research Facility*

How to refer a patient

By Post:

NIHR UCLH Clinical Research Facility,
University College London Hospitals NHS Foundation
Trust, 4th Floor, 170 Tottenham Court Road,
London, W1T 7HA

By Telephone:

Reception: 020344 72929/72930
Reception Fax: 020344 72994

By Email*:

*When referring patients, ensure you use nhs.net emails.
Patient identifiable data *should not* be sent to/via non-
NHS email accounts.

Principal investigator

Prof. John Bridgewater

Dr. Martin Forster

Prof. Daniel Hochhauser

Prof. Sam Janes

Dr. Mark Linch

Prof. Tim Meyer

Dr. Rowan Miller

Dr. Jenny O’Nions

Dr. Dionysis Papadatos-Pastos

Dr. Rakesh Popat

Dr. Rebecca Roylance

Dr. Beatrice Seddon

Dr. Heather Shaw

Dr. Sandra Strauss

Dr. William Townsend



Contents

As it appears in alphabetical order

Breast

Lung

Gynaecological

Sarcoma

Haematology

Solid Tumours

Hepatobiliary

Urology

UCLH Find a Study

To find more information on UCLH CRF Early Phase Cancer Clinical Trials visit the UCLH Find a Study database:

<https://findastudy.uclh.nhs.uk/#/trial>

Using the ‘Study Name’ and/or
‘Local Project Reference’ (LRP).

NIHR UCLH Clinical Research Facility

Cancer Trials Open to Recruitment

For more information on a trial, including eligibility criteria click the hyperlinked **Local Project Reference (LRP)** ID.

Breast

Study Acronym/ Full Title	LPR	PI	Drug Class/ Tumour Target
B-PRECISE-01 (MEN1611-01) Open-label, Multicentre, Phase Ib Dose-escalation Study of MEN1611, a P13K Inhibitor Combined with Trastuzumab ± Fulvestrant, in Subjects with PIK3CA Mutated HER2-positive Locally Recurrent Unresectable (advanced) or Metastatic Breast Cancer Progressed to Anti-HER2 Based Therapy.	120910	Dr. Rebecca Roylance	P13K Inhibitor PIK3CA Mutated HER2-positive Locally Recurrent Unresectable (advanced) or Metastatic Breast Cancer

Gynaecological

Study Acronym/ Full Title	LPR	PI	Drug Class/ Tumour Target
GCT1015-05 ENGOT innovaTV 205: A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax-TF-ADC) in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer.	113569	Dr. Rowan Miller	Antibody-Drug Conjugate (ADC) Targeting Tissue Factor (TF) Recurrent or Stage IVB Cervical Cancer

Haematology

Study Acronym/ Full Title	LPR	PI	Drug Class/ Tumour Target
AML1001 A Phase 1, First in Human (FIH), Dose Escalation Study of JNJ-74856665 (dihydroorotate dehydrogenase [DHODH] Inhibitor) in Participants with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	135994	Dr. Jenny O'Nions	Dihydroorotate Dehydrogenase (DHODH) Inhibitor Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
ASTX660 Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas.	106548	Dr. William Townsend	Dual Antagonist of Cellular Inhibitor of Apoptosis cIAP & XIAP Relapsed T-Cell Lymphomas
BP41072 An Open-Label, Phase I Study To Evaluate The Safety, Pharmacokinetics And Preliminary Antitumor Activity Of Ro7227166 (A Cd19 Targeted 4-1bb Ligand) In Combination With Obinutuzumab And Incombination With Ro7082859 (Cd20-Tcb) Following A Pre-Treatment Dose Of Obinutuzumab Administered In Participants With Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma.	129333	Dr. William Townsend	Ro7227166 (CD19-directed 41BB ligand) + Obinutuzumab (anti-CD20 Monoclonal Antibody) or Glofitamab (CD3-CD20 T-Cell Bispecific Antibody) Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Haematology (II)

Study Acronym/ Full Title	LRP	PI	Drug Class/ Tumour Target
<p>BP42233: GRACE An Open-Label, Multicenter, Phase I Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7425781 In Participants With Relapsed Or Refractory Multiple Myeloma</p>	137532	Dr. Rakesh Popat	<p>Novel T-cell Bispecific Antibody targeting GPRC5D on MM tumour cells and CD3 on T-cells</p> <p>Relapsed or Refractory Multiple Myeloma</p>
<p>CC-220-MM-001 A Phase 1B/2A Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-220 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma.</p>	16/0336	Dr. Rakesh Popat	<p>Cereblon E3 Ligase Modulator</p> <p>Relapsed and Refractory Multiple Myeloma</p>
<p>CC-92480-MM-001 A Phase 1 Multicenter, Open-Label Study to Assess The Safety, Pharmacokinetics And Preliminary Efficacy of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed And Refractory Multiple Myeloma.</p>	18/0040	Dr. Rakesh Popat	<p>Cereblon E3 Ligase Modulator</p> <p>Relapsed and Refractory Multiple Myeloma</p>
<p>CL1-65487-003 Phase I / II, open label, dose escalation part (phase I) followed by non-comparative expansion part (phase II), multicentre study, evaluating safety, pharmacokinetics and efficacy of S65487, a Bcl2 inhibitor combined with azacitidine in adult patients with previously untreated acute myeloid leukemia not eligible for intensive treatment.</p>	136715	Dr. Jenny O’Nions	<p>BCL-2 Inhibitor</p> <p>Previously Untreated Acute Myeloid Leukaemia, not eligible for Intensive Treatment</p>
<p>CO41942 Ph1b study of bispecifics with lenalidomide in relapsed/ refractory FL.</p>	130416	Dr. William Townsend	<p>CD3-CD20 Bispecific Antibody</p> <p>Relapsed or Refractory Follicular Lymphoma</p>
<p>DREAMM-6 A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lenalidomide Plus Dexamethasone (Treatment Arm A), or Bortezomib Plus Dexamethasone (Treatment Arm B) in Participants with Relapsed or Refractory Multiple Myeloma.</p>	18/0571	Dr. Rakesh Popat	<p>Humanised Monoclonal Antibody (anti-BCMA)</p> <p>Relapsed or Refractory Multiple Myeloma</p>
<p>EP0042-101 A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies.</p>	134892	Dr. Jenny O’Nions	<p>FLT3 inhibitor & Aurora Kinase Inhibitor</p> <p>Acute Myeloid Leukaemia (AML) or Myelodysplastic Syndromes (MDS)</p>
<p>NVG111-101 NVG111-101: An open-label, phase 1/2, first in human study investigating the safety, tolerability, pharmacokinetics and efficacy of NVG-111 in subjects with relapsed/refractory chronic lymphocytic leukaemia and mantle cell lymphoma.</p>	135715	Dr. William Townsend	<p>Receptor Tyrosine Kinase Like Orphan Like Receptor 1 (ROR1) Bispecific antibody</p> <p>Relapsed or Refractory Chronic Lymphocytic Leukaemia & Mantle Cell Lymphoma</p>

Haematology (III)

Study Acronym/ Full Title	LPR	PI	Drug Class/ Tumour Target
<p>Teclistamab in Relapsed or Refractory Multiple Myeloma</p> <p>A Phase 1/2b, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanised BCMA x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma.</p>	134949	Dr. Rakesh Popat	<p>Humanised Bispecific Antibody (BCMA & CD3)</p> <p>Relapsed or Refractory Multiple Myeloma</p>

Hepatobiliary

Study Acronym/ Full Title	LPR	PI	Drug Class/ Target
<p>ADP-0033-001</p> <p>A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFP^{e332T}) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types.</p>	17/0093	Prof. Tim Meyer	<p>T-Cell Therapy</p> <p>Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumour Types</p>

Lung

Study Acronym/ Full Title	LPR	PI	Drug Class/ Target
<p>TACTICAL</p> <p>Targeted Stromal Cells Expressing TRAIL as a therapy for lung cancer.</p>	14/0453	Prof. Sam Janes	<p>MSC-TRAIL with chemo-immunotherapy as first line therapy</p> <p>Advanced Lung Cancer</p>

Sarcoma

Study Acronym/ Full Title	LPR	PI	Drug Class/ Target
<p>Afatinib in Chordoma</p> <p>A phase 2, single arm, European multi-center trial evaluating the efficacy of afatinib as first-line or later-line treatment in advanced Chordoma.</p>	17/0146	Dr. Sandra Strauss	<p>EGFR Small Molecule Inhibitor</p> <p>Advanced Chordoma</p>
<p>DCC-3014</p> <p>A Multicenter Phase 1, Open-Label Study of DCC-3014 to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors.</p>	128373	Dr. Beatrice Seddon	<p>Tyrosine Kinase Inhibitor.</p> <p>Cohort B only (Expansion Phase) — Tenosynovial Giant Cell Tumour (DTGCT)</p>

Solid Tumours

Study Acronym/ Full Title	LPR	PI	Drug Class/ Target
AGI-134 A phase I/IIa, multicentre, open label study designed to evaluate the safety and tolerability of AGI-134 as monotherapy and in combination with pembrolizumab, in unresectable metastatic solid tumours.	104916	Dr. Martin Forster	Anti-αGal Unresectable Superficial Metastatic Melanoma or Squamous Cell Cancers
BLU-667 A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors.	17/0783	Dr. Martin Forster	RET Inhibitor Thyroid Cancer, NSCLC, Other RET-driven Advanced Solid Tumours
CRUKD/17/009: BICYCLE Study A Cancer Research UK Phase I/IIa trial of BT1718, (A Bicycle drug conjugate), given intravenously in patients with advanced solid tumours.	100211	Dr Dionysios Papadatos-Pastos	Bicycle Drug Conjugate Advanced Solid Tumours
Cancer Peptide Vaccine Open-label, phase 1 study of S-488210/S-488211 to evaluate the safety and tolerability in patients with unresectable recurrent and/or metastatic solid tumor.	119614	Dr. Mark Linch	5-peptide cancer vaccine Unresectable recurrent and/or Metastatic Solid Tumour
D9170C00001 A Phase I/IIa, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD7648 Monotherapy or in Combination with either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients with Advanced Malignancies	18/0580	Dr. Rowan Miller	DNA-PK Inhibitor Advanced Malignancies
FIGHT-207 A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations.	124183	Prof. John Bridgewater	FGFR Inhibitor Advanced/Metastatic or Surgically Unrespectable Solid Tumour Malignancies Harboring Activating FGFR Mutations or Translocations
Garnet A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors.	16/0355	Dr. Rowan Miller	Anti PD-L1 Monoclonal Antibody Cohorts Open: <i>Part 2B: Cohort A1</i> dMMR/MSI-H endometrial cancer <i>Part 2B: Cohort F</i> non-endometrial dMMR/MSI-H & POLE-Mut cancers
IMC-F106C-101 A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers	130728	Dr. Heather Shaw	PRAME Immune-Mobilizing T-Cell Receptor against Cancer HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers
LOXO-TRK-15002 LOXO-TRK-15002: A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors.	16/0077	Dr. Martin Forster	TRK Inhibitor NTRK Fusion-Positive Tumours

Solid Tumours (II)

Study Acronym/ Full Title	LPR	PI	Drug Class/ Target
<p>MOv18 A Cancer Research UK Phase I study of MOv18 IgE, a first in class chimeric IgE antibody against folate receptor-α, in patients with advanced solid tumours.</p>	17/0121	Dr. Rowan Miller	<p>IgE Antibody against Folate Receptor-α Advanced solid tumours</p>
<p>MULTI-31 An open-label, Phase II, platform trial evaluating safety and efficacy of multiple BI 754091 anti-PD-1 based combination regimens in PD-(L)1 naïve and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy</p>	123071	Dr. Martin Forster	<p>Anti-PD-L1 Based Combination Regime PD-(L)1 naïve & PD-(L)1 pre-treated patients with advanced and/or metastatic solid tumours, had at least one line of systemic therapy.</p>
<p>Starpharma CTX A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CTX-SPL9111 (a cabazitaxel (CTX)-dendrimer conjugate) in patients with advanced solid tumours.</p>	18/0016	Dr. Martin Forster	<p>Drug-Dendrimer Conjugate Advanced solid tumours</p>
<p>Starpharma DTX A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of DTX-SPL8783 (a docetaxel (DTX)-dendrimer conjugate) as monotherapy in patients with advanced solid tumours or in combination with nintedanib in patients with non-small cell lung cancer (NSCLC).</p>	17/0585	Dr. Martin Forster	<p>Drug-Dendrimer Conjugate (Tubulin Polymerase Inhibitor) Advanced solid tumours Or non-small cell lung cancer (NSCLC)</p>
<p>TACTI-002 (Two ACTIVE Immunotherapeutics): A multicenter, open label, phase II study in patients with previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC), or recurrent PD-X refractory NSCLC or with recurrent or metastatic squamous head and neck cancer (HNSCC) receiving the soluble LAG-3 fusion protein efitilagimod alpha (IMP321) in combination with pembrolizumab (PD-1 antagonist).</p>	18/0560	Dr. Martin Forster	<p>APC Activator & Anti-PD-1 Monoclonal Antibody Previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC), Or recurrent PD-X refractory NSCLC Or with recurrent or metastatic squamous head and neck cancer (HNSCC)</p>

Urology

Study Acronym/ Full Title	LRP	PI	Drug Class/ Target
<p>BXCL701 A Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination with the Anti-Programmed Cell Death 1(PD-1) Monoclonal Antibody Pembrolizumab (PEMBRO; Keytruda®) in Patients with Small Cell Neuroendocrine Prostate Cancer (SCNC; NEPC).</p>	113103	Dr. Mark Linch	<p>Dipeptidyl Peptidases (DPP) Inhibit & Anti-PD-1 Monoclonal Antibody</p> <p>Small Cell Neuroendocrine Prostate Cancer (SCNC; NEPC)</p>
<p>CORT125281 Phase 1/2 Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CORT125281 with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.</p>	18/0135	Dr. Mark Linch	<p>Glucocorticoid Receptor (GR) Antagonist</p> <p>Metastatic Castration-Resistant Prostate Cancer</p>
<p>FIDES-02 An open-label multi-cohort Phase 1/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations (FIDES-02)</p>	124615	Dr. Mark Linch	<p>FGFR Inhibitor & Anti PD-L1 Monoclonal Antibody</p> <p>Advanced Urothelial Cancer expressing FGFR Genetic aberrations.</p> <p><i>Substudy 4:</i> Urothelial progression - FGFR-inhibitor resistant (>12 weeks) & previous chemo and CPI</p>
<p>PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy): A first-in-human, dose titration and expansion trial to evaluate safety, immunogenicity and preliminary efficacy of W_pro1 in patients with metastatic castration resistant prostate cancer and W_pro1 in combination with cemiplimab and/or goserelin acetate in patients with high-risk, localized prostate cancer.</p>	122815	Dr. Mark Linch	<p>W_pro1 mRNA Cancer Vaccine</p> <p><i>Group 1:</i> mCRPC that have exhausted conventional treatment</p> <p><i>Group 2:</i> High-risk, Localized Prostate Cancer prior to Prostatectomy</p>